Lixivaptan

PreclinicalSmall molecule

PPalladio Biosciences

Lixivaptan is one of 4 small molecule programs targeting Polycystic Kidney Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Kidney DiseaseActive, not recruiting

Polycystic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Polycystic Kidney Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

—2

Rapamune

PPrism Pharmaceuticals

Metformin XR

1 4

Lixivaptan

PPalladio Biosciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyponatremia3 trials

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

Completed·CCardioKine Inc.·Phase 3·NCT00876798·206 enrolled

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

Completed·CCardioKine Inc.·Phase 3·NCT00660959·106 enrolled

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

Completed·CCardioKine Inc.·Phase 3·NCT00578695·652 enrolled

Autosomal Dominant Polycystic Kidney Disease3 trials

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Completed·PPalladio Biosciences·Phase 2·NCT03487913·31 enrolled

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Terminated·PPalladio Biosciences·Phase 3·NCT04064346·12 enrolled

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Terminated·PPalladio Biosciences·Phase 3·NCT04152837·7 enrolled

ADPKD1 trial

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Terminated·PPalladio Biosciences·Phase 3·NCT05208866·1 enrolled

Congestive Heart Failure1 trial

Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

Completed·CCardioKine Inc.·Phase 2·NCT01055912·170 enrolled

Women1 trial

A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study

Completed·CCardioKine Inc.·Phase 1·NCT00675701·298 enrolled

2 more indications

Heart Failure1 trial

International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia

Withdrawn·CCardioKine Inc.·Phase 3·NCT00876876·300 enrolled

Polycystic Kidney Disease1 trial

Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

No longer available·PPalladio Biosciences··NCT03717181

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lixivaptan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lixivaptan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lixivaptan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Palladio Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPalladio Biosciences

Lixivaptan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyponatremia3 trials

Autosomal Dominant Polycystic Kidney Disease3 trials

ADPKD1 trial

Congestive Heart Failure1 trial

Women1 trial

Heart Failure1 trial

Polycystic Kidney Disease1 trial

References

Drug Info

Quick Facts

Related News